The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Open accessAbstract
BACKGROUND: Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic sclerosis-related death. Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis and ILD. METHODS: We conducted a randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of nintedanib in patients with ILD associated with systemic sclerosis. Patients who had systemic sclerosis with an onset of the first non-Raynaud's symptom within the past 7 years and a high-resolution computed tomographic scan that showed fibrosis affecting at least 10% of the lungs were randomly assigned, in a 1:1 ratio, to receive 150 mg of nintedanib, administered orally twice daily, or placebo. The primary end point was the annual rate of decline in forced vital capacity (FVC), assessed over a 52-week period. Key secondary end points were absolute changes from baseline in the modified Rodnan skin score and in the total score on the St. George's Respiratory Questionnaire (SGRQ) at week 52. RESULTS: A total of 576 patients received at least one dose of nintedanib or placebo; 51.9% had diffuse cutaneous systemic sclerosis, and 48.4% were receiving mycophenolate at baseline. In the primary end-point analysis, the adjusted annual rate of change in FVC was -52.4 ml per year in the nintedanib group and -93.3 ml per year in the placebo group (difference, 41.0 ml per year; 95% confidence interval [CI], 2.9 to 79.0; P = 0.04). Sensitivity analyses based on multiple imputation for missing data yielded P values for the primary end point ranging from 0.06 to 0.10. The change from baseline in the modified Rodnan skin score and the total score on the SGRQ at week 52 did not differ significantly between the trial groups, with differences of -0.21 (95% CI, -0.94 to 0.53; P = 0.58) and 1.69 (95% CI, -0.73 to 4.12 [not adjusted for multiple comparisons]), respectively. Diarrhea, the most common adverse event, was reported in 75.7% of the patients in the nintedanib group and in 31.6% of those in the placebo group. CONCLUSIONS: Among patients with ILD associated with systemic sclerosis, the annual rate of decline in FVC was lower with nintedanib than with placebo; no clinical benefit of nintedanib was observed for other manifestations of systemic sclerosis. The adverse-event profile of nintedanib observed in this trial was similar to that observed in patients with idiopathic pulmonary fibrosis; gastrointestinal adverse events, including diarrhea, were more common with nintedanib than with placebo. (Funded by Boehringer Ingelheim; SENSCIS ClinicalTrials.gov number, NCT02597933.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This observation is therefore in accordance with recent clinical trials showing that antifibrotic therapies are effective in progressive fibrotic interstitial lung diseases other than IPF [20,26,27].”
In the citing paper
“nintedanib has also now been approved for systemic sclerosis (SSc)-associated ILD (SSc-ILD), based on the positive outcome of Safety and Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS) trial (Distler et al., 2019).”
From Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies (2023) · cites this paper as Distler et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationvan den Hoogen, F. H. J., Khanna, D., Fransen, J., Johnson, S. R., Baron, M. G., Tyndall, A., Matucci‐Cerinic, M., Naden, R. P., Medsger, T. A., Carreira, P. E., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204424 · Cited by 2,881
Self-citationThe St George's Respiratory Questionnaire
Jones, P., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,729
Cyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Self-citationInterstitial Lung Disease in Systemic Sclerosis
Goh, N. S. L., Desai, S. R., Veeraraghavan, S., Hansell, D. M., Copley, S. J., Maher, T. M., Corte, T. J., Sander, C. R., Ratoff, J. C., Devaraj, A., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-877oc · Cited by 1,249
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationTashkin, D. P., Roth, M. D., Clements, P. J., Furst, D. E., Khanna, D., Kleerup, E. C., Goldin, J. G., Arriola, E., Volkmann, E. R., Kafaja, S., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30152-7 · Cited by 1,077
Self-citationMode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005
Self-citationWalker, U. A., Tyndall, A., Czirják, L., Denton, C. P., Farge, D., Kowal‐Bielecka, O., Müller‐Ladner, U., Bocelli‐Tyndall, C., & Matucci‐Cerinic, M. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062901 · Cited by 927
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,000
Liang, J., Cao, H., Yang, Y., Ke, Y., Yu, Y., Sun, C., Yue, L., & Lin, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.626953 · Cited by 42
Mummy, D. G., Bier, E. A., Wang, Z., Korzekwinski, J., Morrison, L. D., Barkauskas, C. E., McAdams, H. P., Tighe, R. M., Driehuys, B., & Mammarappallil, J. G. (2021) · Radiology · doi:10.1148/radiol.2021204149 · Cited by 42
Diesler, R., & Cottin, V. (2022) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2022.2089116 · Cited by 42
Melanocortin 1 Receptor (MC1R): Pharmacological and Therapeutic Aspects
Mun, Y. W., Kim, W. H., & Shin, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512152 · Cited by 46
Further insight into systemic sclerosis from the vasculopathy perspective
Ren, H., Liu, L., Xiao, Y., Shi, Y., Zeng, Z., Ding, Y. P., Zou, P., & Xiao, R. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115282 · Cited by 41
The Role of Inflammation and Fibrosis in Interstitial Lung Disease Treatment Decisions
Behr, J., Salisbury, M. L., Walsh, S. L. F., Podolanczuk, A. J., Hariri, L. P., Hunninghake, G. M., Kolb, M. R. J., Ryerson, C. J., Cottin, V., Beasley, M. B., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202401-0048pp · Cited by 44
Self-citationCurrent and Potential New Targets in Systemic Sclerosis Therapy: a New Hope
Hinchcliff, M., & O’Reilly, S. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00918-3 · Cited by 41
Natural variability in the disease course of SSc-ILD: implications for treatment
Vonk, M. C., Walker, U. A., Volkmann, E. R., Kreuter, M., Johnson, S. R., & Allanore, Y. (2021) · European Respiratory Review · doi:10.1183/16000617.0340-2020 · Cited by 44
Treatment for systemic sclerosis-associated interstitial lung disease
Roofeh, D., Lescoat, A., & Khanna, D. (2021) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000795 · Cited by 41
Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies
Lescoat, A., Roofeh, D., Kuwana, M., Lafyatis, R., Allanore, Y., & Khanna, D. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08891-0 · Cited by 41
Self-citationEarly Radiographic Progression of Scleroderma
Volkmann, E. R., Tashkin, D. P., Roth, M. D., Goldin, J. G., & Kim, G. H. J. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.11.033 · Cited by 41
Zanatta, E., Huscher, D., Ortolan, A., Avouac, J., Airó, P., Balbir‐Gurman, A., Siegert, E., Matucci‐Cerinic, M., Cozzi, F., Riemekasten, G., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac188 · Cited by 41
Self-citationNew Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics
Ebata, S., Yoshizaki‐Ogawa, A., Sato, S., & Yoshizaki, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154631 · Cited by 41
Dysregulated B cell function and disease pathogenesis in systemic sclerosis
Beesley, C., Goldman, N. R., Taher, T. E. I., Denton, C. P., Abraham, D., Mageed, R. A., & Ong, V. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.999008 · Cited by 41
Raman, L., Stewart, I. D., Barratt, S. L., Chua, F., Chaudhuri, N., Crawshaw, A., Gibbons, M., Hogben, C., Hoyles, R. K., Kouranos, V., et al. (2022) · ERJ Open Research · doi:10.1183/23120541.00423-2022 · Cited by 40
Fretheim, H., Halse, A., Seip, M., Bitter, H., Wallenius, M., Garen, T., Salberg, A., Brunborg, C., Midtvedt, Ø., Molberg, Ø., et al. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa026 · Cited by 40
A Defect in Thymic Tolerance Causes T Cell–Mediated Autoimmunity in a Murine Model of COPA Syndrome
Deng, Z., Law, C. S., Ho, F. O., Wang, K. M., Jones, K. D., Shin, J., & Shum, A. K. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000028 · Cited by 41
Assassi, S., Li, N., Volkmann, E. R., Mayes, M. D., Rünger, D., Ying, B., Roth, M. D., Hinchcliff, M., Khanna, D., Frech, T., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41627 · Cited by 40
Self-citationReal-life prevalence of progressive fibrosing interstitial lung diseases
Gagliardi, M., Berg, D. V., Heylen, C. E., Koenig, S., Hoton, D., Tamirou, F., Pieters, T., Ghaye, B., & Froidure, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-03481-8 · Cited by 40
Interstitial pneumonia with autoimmune features: challenges and controversies
Mackintosh, J. A., Wells, A. U., Cottin, V., Nicholson, A. G., & Renzoni, E. A. (2021) · European Respiratory Review · doi:10.1183/16000617.0177-2021 · Cited by 42
Ntatsoulis, K., Karampitsakos, Τ., Tsitoura, E., Stylianaki, E.-A., Matralis, A. N., Tzouvelekis, A., Antoniou, K. M., & Aidinis, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.687397 · Cited by 41
Ghuman, A., Khanna, D., Lin, C. J. F., Furst, D. E., Raghu, G., Martínez, F. J., Zucchetto, M., Huang, S., Jennings, A. C., Nihtyanova, S. I., et al. (2023) · Rheumatology · doi:10.1093/rheumatology/kead234 · Cited by 39
Self-citationDistler, O., Volkmann, E. R., Hoffmann‐Vold, A., & Maher, T. M. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1668269 · Cited by 39
Self-citationAutoantibodies to stratify systemic sclerosis patients into clinically actionable subsets
Mähler, M., Hudson, M., Bentow, C., Roup, F., Beretta, L., Simeón‐Aznar, C. P., del Castillo, A. G., Casas, S., & Fritzler, M. J. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102583 · Cited by 39
Hozumi, H., Kono, M., Hasegawa, H., Yasui, H., Suzuki, Y., Karayama, M., Furuhashi, K., Enomoto, N., Fujisawa, T., Inui, N., et al. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.01.083 · Cited by 39
Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis
Nasser, M., Si-Mohamed, S. A., Turquier, S., Traclet, J., Ahmad, K., Philit, F., Bonniaud, P., Chalabreysse, L., Thivolet-Béjui, F., & Cottin, V. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-02043-5 · Cited by 41
Management of Connective Tissue Disease–related Interstitial Lung Disease
Ahmed, S., & Handa, R. (2022) · Current Pulmonology Reports · doi:10.1007/s13665-022-00290-w · Cited by 38
Clinical, mechanistic, and therapeutic landscape of cutaneous fibrosis
Li, D. J., Berry, C. E., Wan, D. C., & Longaker, M. T. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adn7871 · Cited by 40
Biomarkers in systemic sclerosis
Skaug, B. A., & Assassi, S. (2019) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000656 · Cited by 38
Prognostic value of cardiopulmonary exercise testing in patients with systemic sclerosis
Ewert, R., Ittermann, T., Habedank, D., Held, M., Lange, T. J., Halank, M., Winkler, J., Gläser, S., Olschewski, H., & Kovács, G. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-1003-7 · Cited by 38
Nagaraja, V., Matucci‐Cerinic, M., Furst, D. E., Kuwana, M., Allanore, Y., Denton, C. P., Raghu, G., McLaughlin, V. V., Rao, P. S., Seibold, J. R., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41246 · Cited by 38
Self-citationMoor, C. C., van Leuven, S. I., Wijsenbeek, M. S., & Vonk, M. C. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa607 · Cited by 38
Singh, K., Rathore, U., Rai, M. K., Behera, M. R., Jain, N., Ora, M., Bhadauria, D., Sharma, S., Pande, G., Gambhir, S., et al. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s355881 · Cited by 38
Denton, C. P., Goh, N. S. L., Humphries, S. M., Maher, T. M., Spiera, R., Devaraj, A., Ho, L. A., Stock, C., Erhardt, E. M., Alves, M., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac535 · Cited by 38
Self-citationKuster, S., Jordan, S., Elhaï, M., Held, U., Steigmiller, K., Bruni, C., Cacciapaglia, F., Vettori, S., Siegert, E., Rednic, S., et al. (2022) · RMD Open · doi:10.1136/rmdopen-2022-002477 · Cited by 38
Self-citationCampochiaro, C., Luca, G. D. D., Lazzaroni, M. G., Armentaro, G., Spinella, A., Vigone, B., Ruaro, B., Stanziola, A. A., Benfaremo, D., Lorenzis, E. D., et al. (2023) · RMD Open · doi:10.1136/rmdopen-2022-002850 · Cited by 38
Lescoat, A., Bertoldo, E., Colic, J., Santiago, T., Suliman, Y. A., Emmel, J., Conaghan, P. G., Allanore, Y., & Galdo, F. D. (2024) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2024-226429 · Cited by 37
Kuwana, M., Allanore, Y., Denton, C. P., Distler, J. H. W., Steen, V. D., Khanna, D., Matucci‐Cerinic, M., Mayes, M. D., Volkmann, E. R., Miede, C., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41965 · Cited by 37
Self-citationSystemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches
Benfaremo, D., Svegliati, S., Paolini, C., Agarbati, S., & Moroncini, G. (2022) · Biomedicines · doi:10.3390/biomedicines10010163 · Cited by 40
Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management
Zorzi, E. D., Spagnolo, P., Cocconcelli, E., Balestro, E., Iaccarino, L., Gatto, M., Benvenuti, F., Bernardinello, N., Doria, A., Maher, T. M., et al. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-022-08926-0 · Cited by 39
Self-citationEpidemiology and real-life experience in progressive pulmonary fibrosis
Valenzuela, C., & Cottin, V. (2022) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000908 · Cited by 37
Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation Pneumonitis
Rimner, A., Moore, Z., Lobaugh, S. M., Geyer, A. I., Gelblum, D. Y., Abdulnour, R.-E. E., Shepherd, A. F., Shaverdian, N., Wu, A. J.-C., Cuaron, J. J., et al. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.02.030 · Cited by 36
From inflammation to renal fibrosis: A one-way road in autoimmunity?
Roccatello, D., Lan, H.-Y., Sciascia, S., Sethi, S. M., Fornoni, A., & Glassock, R. J. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103466 · Cited by 38
Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review
Cameli, P., Bargagli, E., Bergantini, L., d’Alessandro, M., Pieroni, M., Fontana, G. A., Sestini, P., & Refini, R. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176187 · Cited by 36
Interstitial Lung Disease in 2020
Guler, S. A., & Corte, T. J. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.03.001 · Cited by 39
Mattoo, H., & Pillai, S. S. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03874-y · Cited by 38
Forestier, A., Gouellec, N. L., Behal, H., Kramer, G. B. G., Perez, T., Sobanski, V., Morell‐Dubois, S., Lambert, M., Hatron, P., HACHULLA, E., et al. (2020) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.02.015 · Cited by 35
Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment
Attanasio, U., Cuomo, A., Pirozzi, F., Loffredo, S., Abete, P., Petretta, M., Marone, G., Bonaduce, D., de Paulis, A., Rossi, F. W., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124430 · Cited by 35
Narváez, J., Lluch, J., Molina‐Molina, M., Vicens‐Zygmunt, V., Luburich, P., Yañez, M. A., & Solé, J. M. N. (2020) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.08.004 · Cited by 35
Expert Perspective: Management of Refractory Inflammatory Myopathy
Lundberg, I. E. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41762 · Cited by 34
Potential Therapeutic Targets of Resveratrol in the Prevention and Treatment of Pulmonary Fibrosis
Ramli, I., Cheriet, T., Posadino, A. M., Giordo, R., Zayed, H., Eid, A. H., & Pintus, G. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2809198 · Cited by 35
Novel and potential future therapeutic options in systemic autoimmune diseases
Balogh, L., Oláh, K., Sánta, S., Majerhoffer, N., & Németh, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1249500 · Cited by 36
An international perspective on the future of systemic sclerosis research
Abraham, D., Black, C. M., Denton, C. P., Distler, J. H. W., Domsic, R. T., Feghali‐Bostwick, C. A., Gourh, P., Hinchcliff, M., Kolling, F., Kuwana, M., et al. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01217-2 · Cited by 34
Self-citationGote-Schniering, J., Benešová, M., Brunner, M., Haller, S., Cohrs, S., Frauenfelder, T., Vrugt, B., Feghali‐Bostwick, C. A., Schibli, R., Distler, O., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02724 · Cited by 35
Self-citationTzilas, V., Τzouvelekis, Α., Bouros, E., Karampitsakos, Τ., Ntassiou, M., Avdoula, E., Trachalaki, A., Antoniou, K. M., Raghu, G., & Bouros, D. E. (2020) · ERJ Open Research · doi:10.1183/23120541.00152-2020 · Cited by 35
Self-citationShumar, J. N., Chandel, A., & King, C. S. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112285 · Cited by 35
Volkmann, E. R., Tashkin, D. P., Silver, R. M., Bostwick, C. F., Assassi, S., Frost, D. B., Leng, M., Wilhalme, H. M., Kim, G. H. J., Goldin, J. G., et al. (2022) · The Lancet Rheumatology · doi:10.1016/s2665-9913(22)00193-x · Cited by 34
Idiopathic and immune‐related pulmonary fibrosis: diagnostic and therapeutic challenges
McLean‐Tooke, A. P., Moore, I., & Lake, F. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1086 · Cited by 34
Decline in forced vital capacity as a surrogate for mortality in patients with pulmonary fibrosis
Maher, T. M., Stowasser, S., Voß, F., Bendstrup, E. M., Kreuter, M., Martínez, F. J., Sime, P. J., & Stock, C. (2023) · Respirology · doi:10.1111/resp.14579 · Cited by 35
Self-citationCTHRC1: An Emerging Hallmark of Pathogenic Fibroblasts in Lung Fibrosis
Mukhatayev, Z., Adilbayeva, A., & Kunz, J. (2024) · Cells · doi:10.3390/cells13110946 · Cited by 37
PARP1 stabilizes FOXN3 to suppress pulmonary fibrosis through p38-related feedback regulation
Zhu, X., Huo, Q., Jin, L., Du, J., Yu, J., Wang, H., Wu, N., Li, Y., Rui, Y., Zhao, C., et al. (2026) · Science Advances · doi:10.1126/sciadv.ady1681 · Cited by 33
Khanna, D., Maher, T. M., Volkmann, E. R., Allanore, Y., Smith, V. M., Assassi, S., Kreuter, M., Hoffmann‐Vold, A., Kuwana, M., Stock, C., et al. (2023) · RMD Open · doi:10.1136/rmdopen-2022-002859 · Cited by 33
Self-citationGuler, S. A., Sarbu, A.-C., Stalder, O., Allanore, Y., Bernardino, V., Distler, J. H. W., Gabrielli, A., Hoffmann‐Vold, A., Matucci‐Cerinic, M., Müller‐Ladner, U., et al. (2023) · Thorax · doi:10.1136/thorax-2023-220541 · Cited by 35
Self-citationAn Open-label Study With Pirfenidone on Chronic Hypersensitivity Pneumonitis
Mateos‐Toledo, H., Mejía, M. E., Rodríguez-Barreto, Ó., Mejía-Hurtado, J. G., Rojas‐Serrano, J., Estrada, A., Castillo-Pedroza, J., Castillo-Castillo, K., Gaxiola, M., Buendía-Roldán, I., et al. (2019) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2019.08.019 · Cited by 33
Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence
Vonk, M. C., Smith, V. M., Sfikakis, P. P., Cutolo, M., Galdo, F. D., & Seibold, J. R. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102978 · Cited by 33
Assassi, S., Volkmann, E. R., Zheng, W. J., Wang, X., Wilhalme, H. M., Lyons, M. A., Roth, M. D., & Tashkin, D. P. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221313 · Cited by 32
Gotschy, A., Jordan, S., Stoeck, C. T., von Deuster, C., Peer, T., Gastl, M., Vishnevskiy, V., Wissmann, L., Dobrota, R. D., Mihai, C., et al. (2022) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeac094 · Cited by 32
Self-citationYang, M., Wu, Y., Liu, X., Zhao, C., Li, T., Li, T.-Q., Zhang, X., Jiang, H., Mao, B., & Liu, W. Q. (2023) · Respiratory Medicine · doi:10.1016/j.rmed.2023.107329 · Cited by 32
HSP47: A Therapeutic Target in Pulmonary Fibrosis
Sakamoto, N., Okuno, D., Tokito, T., Yura, H., Kido, T., Ishimoto, H., Tanaka, Y., & Mukae, H. (2023) · Biomedicines · doi:10.3390/biomedicines11092387 · Cited by 33
Stock, C. J. W., Bray, W. G., Kouranos, V., Jacob, J., Kokosi, M. A., George, P. M., Chua, F., Wells, A. U., Sestini, P., & Renzoni, E. A. (2023) · Respirology · doi:10.1111/resp.14609 · Cited by 32
Ruscitti, P., Allanore, Y., Baldini, C., Barilaro, G., Bocci, E. B., Bearzi, P., Bellis, E., Berardicurti, O., Biaggi, A., Bombardieri, M., et al. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103581 · Cited by 31
Self-citationProgress in the treatment of pulmonary fibrosis
Wijsenbeek, M. S. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30062-x · Cited by 31
Effects of Nintedanib in an Animal Model of Liver Fibrosis
Wollin, L., Togbe, D., & Ryffel, B. (2020) · BioMed Research International · doi:10.1155/2020/3867198 · Cited by 33
Update in Interstitial Lung Disease 2019
Montesi, S. B., Fisher, J. H., Martínez, F. J., Selman, M., Pardo, A., & Johannson, K. A. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202002-0360up · Cited by 32
Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease
Gibson, C. D., Kugler, M. C., Deshwal, H., Munger, J. S., & Condos, R. (2020) · Lung · doi:10.1007/s00408-020-00370-1 · Cited by 31
Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib
Makino, S. (2020) · Modern Rheumatology · doi:10.1080/14397595.2020.1826665 · Cited by 31
Hariri, L. P., Roden, A. C., Chung, J. H., Danoff, S. K., Manjarres, D. C. G., Hartwig, M. G., Kheir, F. M., King, C. S., Kreider, M. E., Lynch, D. A., et al. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202009-1179fr · Cited by 31
Jung, S. M., Park, K., & Kim, K. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220493 · Cited by 31
Liang, M., Matteson, E. L., Abril, A., & Distler, J. H. W. (2022) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x221074457 · Cited by 32
Cameli, P., Alonzi, V., d’Alessandro, M., Bergantini, L., Pordon, E., Guerrieri, M., Refini, R. M., Sestini, P., & Bargagli, E. (2022) · Biomedicines · doi:10.3390/biomedicines10081973 · Cited by 31
Hoffmann‐Vold, A., Volkmann, E. R., Allanore, Y., Assassi, S., Vries-Bouwstra, J. K. D., Smith, V. M., Tschoepe, I., Loaiza, L., Kanakapura, M., & Distler, O. (2022) · The Lancet Rheumatology · doi:10.1016/s2665-9913(22)00215-6 · Cited by 32
Self-citationMoor, C. C., van den Berg, C. A. L., Visser, L., Aerts, J. G. J. V., Cottin, V., & Wijsenbeek, M. S. (2020) · ERJ Open Research · doi:10.1183/23120541.00054-2020 · Cited by 31
Morrisroe, K., Hansen, D., Stevens, W., Ross, L., Sahhar, J., Ngian, G., Hill, C. L., Host, L., Walker, J. G., Proudman, S., et al. (2023) · Rheumatology · doi:10.1093/rheumatology/kead491 · Cited by 31
Ghazipura, M., Macrea, M. M., Herman, D. D., Barnes, H., Knight, S. L., Silver, R. M., Montesi, S. B., Raghu, G., & Hossain, T. (2023) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202301-056oc · Cited by 31
Self-citationJia, M., Liu, Y., Liu, J., Meng, J., Cao, J., Miao, L., Zhang, H., Zhu, Y., Sun, M., & Yang, J. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155997 · Cited by 31
Inamo, J., Takeshita, M., Suzuki, K., Tsunoda, K., Usuda, S., Kuramoto, J., Moody, J., Hon, C.-C., Ando, Y., Sasaki, T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63935-9 · Cited by 31
Detection and classification of systemic sclerosis-related interstitial lung disease: a review
DeMizio, D. J., & Bernstein, E. J. (2019) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000660 · Cited by 30
Southern, B. D. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.87a.ccc026 · Cited by 31
Wang, J., Li, X., Zhong, M., Wang, Y., Zou, L., Wang, M., Gong, X., Wang, X., Zhou, C., Ma, X., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.05.027 · Cited by 30
Underdetection of Interstitial Lung Disease in Juvenile Systemic Sclerosis
Foeldvari, I., Klotsche, J., Hinrichs, B., Helmus, N., Kasapçopur, Ö., Adroviç, A., Sztajnbok, F., Terreri, M. T., Antón, J., Smith, V. M., et al. (2020) · Arthritis Care & Research · doi:10.1002/acr.24499 · Cited by 30
Systemic sclerosis in adults. Part II: management and therapeutics
Jerjen, R., Nikpour, M., Krieg, T. M., Denton, C. P., & Saracino, A. (2022) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.10.066 · Cited by 30
Volkmann, E. R., Kreuter, M., Hoffmann‐Vold, A., Wijsenbeek, M. S., Smith, V. M., Khanna, D., Denton, C. P., Wuyts, W. A., Miede, C., Alves, M., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac091 · Cited by 30
Self-citationLimited efficacy of nintedanib for idiopathic pleuroparenchymal fibroelastosis
Kinoshita, Y., Miyamura, T., Ikeda, T., Ueda, Y., Yoshida, Y., Kushima, H., & Ishii, H. (2022) · Respiratory Investigation · doi:10.1016/j.resinv.2022.03.001 · Cited by 30
Kondo, M., Suzuki, T., Kawano, Y., Kojima, S., Miyashiro, M., Matsumoto, A., Kania, G., Błyszczuk, P., Ross, R. L., Mulipa, P., et al. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-022-02899-3 · Cited by 30
Ramahi, A., Lescoat, A., Roofeh, D., Nagaraja, V., Namas, R. A., Huang, S., Varga, J., O’Dwyer, D. N., Wang, B., Flaherty, K. R., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac639 · Cited by 30
The Challenge of Very Early Systemic Sclerosis: A Combination of Mild and Early Disease?
Blaja, E., Jordan, S., Mihai, C.-M., Dobrota, R. D., Becker, M. O., Maurer, B., Matucci‐Cerinic, M., & Distler, O. (2020) · The Journal of Rheumatology · doi:10.3899/jrheum.190976 · Cited by 30
Self-citationMacrophages and cadherins in fibrosis and systemic sclerosis
To, S., & Agarwal, S. K. (2019) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000657 · Cited by 30
The Rationale for Targeting the JAK/STAT Pathway in Scleroderma-Associated Interstitial Lung Disease
Talotta, R. (2020) · Immunotherapy · doi:10.2217/imt-2020-0270 · Cited by 30
Reproductive Issues and Pregnancy Implications in Systemic Sclerosis
Lazzaroni, M. G., Crisafulli, F., Moschetti, L., Semeraro, P., Cunha, A. R., Neto, A., Lojacono, A., Ramazzotto, F., Zanardini, C., Zatti, S., et al. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08910-0 · Cited by 29
Effects of Ruxolitinib on fibrosis in preclinical models of systemic sclerosis
Bellamri, N., Lelong, M., Joannes, A., Tallec, E. L., Jouneau, S., Vernhet, L., Lescoat, A., & Lecureur, V. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109723 · Cited by 29
Metadata
- Authors
- Distler, O., Highland, K. B., Gahlemann, M., Azuma, A., Fischer, A., Mayes, M. D., Raghu, G., Sauter, W., Girard, M., Alves, M., Clerisme-Beaty, E., Stowasser, S., Tetzlaff, K., Kuwana, M., & Maher, T. M.
- Affiliations
- Cleveland Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-06-27
- Volume
- 380
- Issue
- 26
- Pages
- 2518-2528
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2945521814
- Cited by
- 1,647
- References
- 36
- Citations by year
- 2026: 139 · 2025: 203 · 2024: 215 · 2023: 231 · 2022: 243 · 2021: 299 · 2020: 247 · 2019: 68
- FWCI
- 157.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, systemic sclerosis, systemic sclerosis-associated interstitial lung disease, tyrosine kinase inhibitors, antifibrotic therapy, forced vital capacity decline, pulmonary fibrosis, diffuse cutaneous systemic sclerosis, skin involvement, quality of life, diarrhea, adverse events, mycophenolate, modified Rodnan skin score, St George's Respiratory Questionnaire
- MeSH terms
- Administration, Oral, Adult, Diarrhea, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Scleroderma, Systemic, Vital Capacity, Lung Diseases, Interstitial, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
